SUBSCRIBE Subscribe to our RSS Feed

CMLHope.Com

A Worldwide Support Network For Chronic Myelogenous Leukemia

  • home
  • About
  • Contact
  • Sponsored By RealEstateZoo.Com

Archives

  • February 2012
  • January 2012
  • October 2011
  • September 2011
  • July 2011
  • June 2011
  • May 2011
  • April 2011
  • March 2011
  • February 2011
  • January 2011
  • December 2010
  • November 2010
  • October 2010
  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • September 2007
  • August 2007
  • July 2007
  • June 2007
  • May 2007
  • April 2007
  • March 2007
  • February 2007
  • January 2007
  • December 2006
  • November 2006
  • October 2006
  • September 2006
  • August 2006
  • July 2006
  • June 2006
  • May 2006
  • April 2006
  • March 2006
  • February 2006
  • January 2006
  • December 2005
  • November 2005
  • October 2005
  • September 2005
  • August 2005
  • July 2005
  • June 2005
  • May 2005
  • April 2005
  • March 2005
  • February 2005
  • January 2005
  • December 2004
  • November 2004
  • October 2004
  • September 2004
  • August 2004
  • July 2004
  • June 2004

Recent Posts

  • Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
  • Caregiving Burden, Stress, and Health Effects Among Family Caregivers of Adult Cancer Patients [Grand Rounds]
  • Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
  • Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
  • Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.
  • Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
  • Imatinib and beyond – targeting activated tyrosine kinases in myeloproliferative disorders.
  • Recent developments and future perspectives of personalized oncology.
  • [Mechanism of cinnamic aldehyde-inducing apoptosis of chronic myeloid leukemic cells in vitro].
  • [Expression of CIAPIN1 gene in BMMNC of patients with leukemia].
  • Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells
  • CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression
  • Perspectives on Targeted Therapies for Treatment of Human Cancers: Predictors of Response to Targeted Therapies for Gastrointestinal Stromal Tumors.
  • Modeling of Molecular Interaction between Apoptin, BCR-Abl and CrkL – An Alternative Approach to Conventional Rational Drug Design.
  • Ponatinib: Targeting the T315I Mutation in Chronic Myelogenous Leukemia.

 

December 2006
M T W T F S S
« Nov   Jan »
 123
45678910
11121314151617
18192021222324
252627282930  

Meta

  • Log in
  • Entries RSS
  • Comments RSS
  • WordPress.org

CML Articles 12/11/2006

Posted by rob on December 11, 2006 under Uncategorized | Be the First to Comment

Recurrent disseminated skin lesions due to Metarrhizium anisopliae in an adult patient with acute myelogenous leukaemia.
Maculopapular skin rashes associated with high-dose chemotherapy: prevalence and risk factors.
[Attentive questions about treatment of chronic myelogenous leukemia with imatinib mesylate]
[Effects
and prognostic factors of HLA-matched sibling donor allogeneic
hematopoietic stem cell transplantation for chronic myelogenous
leukemia]
Dose Modification of Imatinib by Monitoring the Level of BCR-ABL Transcript in Chronic Myelogenous Leukemia.
Targeted Degradation of the AML1/MDS1/EVI1 Oncoprotein by Arsenic Trioxide.
RALBP1/RLIP76 mediates multidrug resistance.
A Primitive Cell Origin for B-Cell Precursor ALL?
A new biodegradable and biocompatible hydrogel with polyaminoacid structure.

Lights

Posted by rob on December 9, 2006 under Uncategorized | Be the First to Comment

From chutney bannister

home top

Site Information

© 2012 CMLHope.Com
Ministry Free Theme
by eGrace Creative.

Pages

  • Home
  • About
  • Contact
  • Sponsored By RealEstateZoo.Com

Blogroll

    Contributors

    • MedWorm Query: +chronic +myelogenous +leukemia
    • pubmed: myelogenous